Lexaria Bioscience Corp. (LEXX) Key Metrics
LEXX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.0M
- Enterprise value
- $3.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 31.1 10-yr median 30.7
- Price / book
- 1.4 10-yr median 5.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.60
LEXX key metrics, FY2016–FY2025
Fiscal year ended August 31, 2025 · U.S. dollarsLEXX valuation Price multiples at each fiscal year-end price.
Price / sales−78.5%
22.4
FY2025 · hover or tap a bar for each year
FY2016FY2025
Price / book−12.1%
5.3
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow yield−55.8 pts
−66.1%
FY2025 · hover or tap a bar for each year
FY2016FY2025
LEXX returns How much profit the business earns on the capital it uses.
Return on equity−111.3 pts
−215.9%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Return on invested capital−411.2 pts
−682.7%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Return on assets−85.5 pts
−182.5%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Asset turnover+39.3%
0.11
FY2025 · hover or tap a bar for each year
FY2016FY2025
LEXX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+4.6%
$0.59
FY2025 · hover or tap a bar for each year
FY2016FY2025
Earnings per share
−$9.92
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow per share
−$8.73
FY2025 · hover or tap a bar for each year
FY2016FY2025
Book value per share−74.4%
$2.49
FY2025 · hover or tap a bar for each year
FY2016FY2025
Shares outstanding+45.3%
1.2M
FY2025 · hover or tap a bar for each year
FY2016FY2025
LEXX financial health Debt, liquidity and how easily interest is covered.
Debt / equity+113.9%
0.04
FY2025 · hover or tap a bar for each year
FY2016FY2025
Net debt+$4.6M
−$1.9M
FY2025 · hover or tap a bar for each year
FY2016FY2025
Current ratio−67.7%
2.32
FY2025 · hover or tap a bar for each year
FY2016FY2025
Debt / assets+69.0%
0.03
FY2025 · hover or tap a bar for each year
FY2016FY2025
LEXX efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−45 days
85 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Days payables outstanding+114,012 days
162,568 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Cash conversion cycle−114,057 days
-162,483 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Capex / revenue−5.8 pts
3.5%
FY2025 · hover or tap a bar for each year
FY2016FY2025
LEXX valuation history
Fiscal year-endToday10-year median
LEXX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LEXX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LEXX price vs earnings per share
Share price at year-endEPS (right axis)
LEXX key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $15.8M | $48.4M | $6.9M | — | — | — | — | — | — | — |
| Enterprise value | $14.0M | $42.0M | $5.6M | — | — | — | — | — | — | — |
| Price / sales | 22.4 | 104.3 | 30.7 | — | — | — | — | — | — | — |
| Price / book | 5.3 | 6.0 | 2.3 | — | — | — | — | — | — | — |
| EV / sales | 19.8 | 90.5 | 24.9 | — | — | — | — | — | — | — |
| Earnings yield | −75.1% | −12.0% | −96.0% | — | — | — | — | — | — | — |
| Free cash flow yield | −66.1% | −10.3% | −87.1% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $13.20 | $58.65 | $15.75 | $44.40 | $93.30 | $0.00 | $0.00 | $0.01 | $0.00 | $0.01 |
| Per share | ||||||||||
| Revenue per share | $0.59 | $0.56 | $0.51 | — | — | — | — | — | — | — |
| Earnings per share | −$9.92 | −$7.02 | −$15.12 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$8.71 | −$6.01 | −$13.34 | — | — | — | — | — | — | — |
| Free cash flow per share | −$8.73 | −$6.06 | −$13.72 | — | — | — | — | — | — | — |
| Cash per share | $1.64 | $7.94 | $3.35 | — | — | — | — | — | — | — |
| Book value per share | $2.49 | $9.73 | $6.90 | — | — | — | — | — | — | — |
| Tangible book value per share | $2.24 | $9.11 | $5.85 | — | — | — | — | — | — | — |
| Capex per share | $0.02 | $0.05 | $0.38 | — | — | — | — | — | — | — |
| Debt per share | $0.09 | $0.17 | $0.37 | — | — | — | — | — | — | — |
| Shares outstanding | 1.2M | 826K | 441K | — | — | — | — | — | — | — |
| Change in shares outstanding | +45.3% | +87.2% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −215.9% | −104.6% | −121.3% | −68.5% | −51.0% | −160.3% | −171.8% | −244.7% | −114.2% | −234.0% |
| Return on invested capital (ROIC) | −682.7% | −271.5% | −289.3% | −303.2% | −301.6% | −272.9% | −379.0% | −888.0% | −399.7% | −266.4% |
| Return on assets (ROA) | −182.5% | −97.0% | −122.1% | −68.9% | −50.0% | −143.0% | −160.5% | −249.4% | −109.1% | −190.1% |
| Return on tangible assets | −307.8% | −69.4% | −254.3% | −99.0% | −31.2% | −155.1% | −170.1% | −288.8% | −66.8% | −237.0% |
| Free cash flow margin | — | — | — | — | −563.0% | −689.8% | — | −600.8% | — | — |
| Financial health | ||||||||||
| Total debt | $109,320 | $137,366 | $163,967 | $49,988 | $97,319 | $156,101 | — | $7,855 | $42,690 | $45,000 |
| Cash & short-term investments | $2.0M | $6.6M | $1.5M | $6.2M | $11.8M | $1.3M | $1.3M | $1.7M | $2.5M | $93,409 |
| Net debt | −$1.9M | −$6.4M | −$1.3M | −$6.1M | −$11.7M | −$1.2M | −$1.3M | −$1.7M | −$2.5M | −$48,409 |
| Debt / equity | 0.04 | 0.02 | 0.05 | 0.01 | 0.01 | 0.06 | — | 0.00 | 0.01 | 0.17 |
| Debt / assets | 0.03 | 0.02 | 0.05 | 0.01 | 0.01 | 0.06 | — | 0.00 | 0.01 | 0.08 |
| Current ratio | 2.32 | 7.18 | 8.22 | 35.96 | 81.18 | 8.53 | 9.86 | 52.34 | 30.27 | 1.18 |
| Quick ratio | 2.32 | 7.18 | 8.22 | 35.76 | 80.99 | 8.01 | 9.17 | 50.34 | 29.54 | 0.87 |
| Interest coverage | — | — | — | -57.9 | — | — | — | — | -308.4 | -547.1 |
| Working capital | $2.0M | $6.8M | $1.9M | $6.8M | $12.3M | $1.7M | $1.6M | $2.2M | $2.7M | $76,285 |
| Invested capital | $1.1M | $1.6M | $1.7M | $1.8M | $1.6M | $1.4M | $1.0M | $658,706 | $515,660 | $217,636 |
| Tangible asset value | $2.3M | $7.1M | $2.2M | $7.1M | $12.7M | $2.2M | $2.2M | $2.2M | $2.7M | $33,760 |
| Net current asset value | $1.9M | $6.7M | $1.8M | $6.8M | $12.2M | $1.6M | $1.6M | $2.2M | $2.7M | $31,285 |
| Graham net-net per share | $0.44 | $6.62 | $2.73 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | 3.5% | 9.3% | 75.0% | 19.3% | 11.0% | 8.7% | 345.5% | 19.7% | 15.2% | 49.4% |
| Capex / depreciation | 0.28 | 0.56 | 1.17 | 0.48 | 0.54 | 0.23 | 12.70 | 37.02 | 6.52 | 32.47 |
| Stock-based compensation / revenue | 121.8% | 106.0% | 75.3% | 294.7% | 56.7% | 296.3% | 281.5% | 600.6% | 177.6% | 299.7% |
| R&D / revenue | 1,167.1% | 508.4% | 1,621.0% | 721.5% | 174.7% | 100.7% | 249.6% | 113.8% | 85.1% | 22.2% |
| SG&A / revenue | 615.5% | 829.7% | 1,353.6% | 1,942.0% | 687.8% | 1,034.3% | 1,636.6% | 1,503.2% | 2,880.4% | 2,987.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 84.9 | 129.6 | 304.2 | 388.9 | 165.7 | 278.6 | 441.8 | 131.0 | 505.8 | 728.2 |
| Days of inventory on hand | — | — | 222.6 | 172.9 | 152.5 | 448.6 | 1,711.0 | 1,118.9 | 1,238.5 | 1,211.1 |
| Days payables outstanding | 162,567.6 | 48,555.1 | 1,999.9 | 571.7 | 156.1 | 140.6 | 365.4 | 340.2 | 752.0 | 492.4 |
| Cash conversion cycle (days) | -162,482.7 | -48,425.5 | -1,473.1 | -9.9 | 162.1 | 586.6 | 1,787.4 | 909.7 | 992.3 | 1,446.8 |
| Receivables turnover | 4.30 | 2.82 | 1.20 | 0.94 | 2.20 | 1.31 | 0.83 | 2.79 | 0.72 | 0.50 |
| Payables turnover | 0.00 | 0.01 | 0.18 | 0.64 | 2.34 | 2.60 | 1.00 | 1.07 | 0.49 | 0.74 |
| Inventory turnover | — | — | 1.64 | 2.11 | 2.39 | 0.81 | 0.21 | 0.33 | 0.29 | 0.30 |
| Asset turnover | 0.11 | 0.08 | 0.04 | 0.02 | 0.09 | 0.14 | 0.09 | 0.16 | 0.04 | 0.06 |
| Average receivables | $164,238 | $164,861 | $188,514 | $272,092 | $328,163 | $293,535 | $269,448 | $155,522 | $88,188 | $81,232 |
| Average payables | $1.2M | $641,460 | $172,592 | $112,518 | $74,986 | $38,272 | $22,920 | $23,476 | $61,292 | $61,542 |
| Average inventory | — | — | $19,210 | $34,033 | $73,260 | $122,134 | $107,314 | $77,204 | $100,949 | $151,355 |
| Intangibles / total assets | 7.4% | 5.8% | 15.0% | 6.2% | 2.7% | 10.3% | 9.9% | 6.0% | 2.2% | 9.5% |
Computed from LEXX's annual financial statements (latest annual report filed November 28, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LEXX valuation and financial ratios
Lexaria Bioscience earned a return on equity of −215.9% and a return on invested capital of −682.7% in fiscal 2025. It ended the year with $0.1 million of debt and $2.0 million in cash and short-term investments, a net cash position of $1.9 million.
See the LEXX income statement, the LEXX chart for price history, or the LEXX stock overview for the latest quote and news.
LEXX key metrics FAQ
What is Lexaria Bioscience's return on equity?
Lexaria Bioscience's return on equity (ROE) was −215.9% in fiscal 2025: net income of -$11.9 million on average shareholders' equity of $5.5 million.
What is Lexaria Bioscience's ROIC?
Lexaria Bioscience's return on invested capital was −682.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lexaria Bioscience have?
Lexaria Bioscience had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
What is Lexaria Bioscience's free cash flow yield?
Lexaria Bioscience generated -$10.5 million of free cash flow in fiscal 2025, a free cash flow yield of −66.1% on its market value at year-end ($15.8 million).
What is Lexaria Bioscience's current ratio?
Lexaria Bioscience's current ratio was 2.32 at the end of fiscal 2025: current assets were 2.32 times current liabilities.